King’s College London, Wellcome Trust, Advent Venture set up new biotech company

CoCo Therapeutics will work to develop new treatments for Alzheimer’s disease, which is based on the research of Prof. Jonathan Corcoran.

The company, which will be funded through the Wellcome Trust’s Seeding Drug Discovery initiative, will investigate the role of the retinoic acid receptor, RAR-alpha, and molecules that act on Alzheimer’s disease.

Advent Venture’s general partner Dr Raj Parekh will become the founding chairman of CoCo Therapeutics.

King’s College London neuroscience drug discovery unit director Prof. Jonathan Corcoran said, "I am delighted to be working with Advent on this project. Our research has shown early promise in this area and this partnership will enable us to progress the work further. This is an exciting step forward in the search for effective Alzheimer’s disease treatments."